Nyxoah SA

Nyxoah SA announced it received $15 million from the European Investment Bank, completing a total of $110 million in new capital raised in June 2026, including a recent equity offering. This non-dilutive debt funding will accelerate the US commercial launch of its Genio system, support R&D, and scale up manufacturing. Additionally, the company scheduled an extraordinary shareholders' meeting for July 9, 2026, to renew its authorized capital, and disclosed several transparency notifications regarding changes in major shareholdings.

Nyxoah SA announced it will host an Investor and Analyst Day on July 8, 2026, in New York. The event will feature the company's leadership team and Board discussing U.S. commercial execution, growth strategy, and key priorities for its Genio system. Key topics will include Genio U.S. launch momentum, market dynamics, reimbursement, and the company's path to profitability.

Nyxoah SA announced it received $15 million from the European Investment Bank (EIB), representing the second tranche of its loan facility. This non-dilutive debt funding, combined with a recent equity raise, brings the total capital raised in June 2026 to $110 million. The proceeds are primarily intended to accelerate the commercial launch of the Genio system in the United States, support research and development, and scale up manufacturing. CEO Olivier Taelman stated this financing completes a transformative period for the company, positioning it strongly for its next growth phase.

Nyxoah SA announced that its Genio® hypoglossal nerve stimulation therapy for Obstructive Sleep Apnea (OSA) received the prestigious Prix Galien UK 2026 Award for Best Medical Technology. This award is a significant recognition of Genio's impact on patient care and outcomes. The company highlighted recent business momentum, including FDA approval and commercial launch in the U.S., new financing to accelerate U.S. expansion, and increasing adoption across Europe and other international markets.

Nyxoah SA provided an update on its total number of voting rights and shares following the issuance of 55,232,558 new shares from a previously announced underwritten public offering. The company's total share capital now stands at EUR 7,073,687.00, with 99,926,284 total voting rights. Additionally, the company reported 3,322,832 granted subscription rights and 225 convertible bonds that could result in 12,618,243 voting rights upon conversion.

Nyxoah SA has completed $110 million in aggregate financings, consisting of a $95 million equity financing and an anticipated $15 million second tranche from its European Investment Bank loan. This capital infusion is earmarked to accelerate the U.S. commercial launch of its Genio system for Obstructive Sleep Apnea (OSA). The company aims to leverage this funding to drive U.S.-driven growth and long-term value creation, building on its initial commercial momentum in the U.S. with 40 sales representatives.

Nyxoah SA announced the closing of its underwritten public offering, generating approximately $95.0 million in gross proceeds from the sale of 55,232,558 ordinary shares at $1.72 per share. The company plans to use the net proceeds to expand commercialization activities in the U.S. and internationally, fund research and development for its Genio system, and for general corporate purposes including potential debt repayment and acquisitions. Additionally, Nyxoah intends to draw EUR 13.8 million from its European Investment Bank loan in the second quarter of 2026.

Nyxoah SA announced the pricing of an underwritten public offering of approximately 55.2 million ordinary shares at $1.72 per share, expected to raise gross proceeds of $95 million. The company also granted underwriters an option to purchase additional shares. Net proceeds are estimated at $88.5 million and will be used for commercialization, R&D, and general corporate purposes. The offering is expected to close around June 9, 2026. Additionally, certain directors indicated interest in participating in the offering.

Nyxoah SA announced the pricing of an underwritten public offering of 55,232,558 ordinary shares at $1.72 per share, expecting to raise approximately $95 million in gross proceeds. The company has also granted underwriters an option to purchase additional shares. Nyxoah intends to use the net proceeds to expand commercialization activities in the United States, finance research and development for Genio system upgrades, advance commercialization in international markets, and for general corporate purposes, including potential debt repayment and acquisitions. The offering is expected to close around June 9, 2026.

Nyxoah SA announced a leadership transition, initiating a search for a U.S.-based Chief Executive Officer to accelerate its U.S. commercial growth. Current CEO Olivier Taelman will remain engaged during the transition. The company also provided updates on its liquidity, reporting 25.9 million in cash and equivalents as of March 31, 2026, with a cash runway into Q3 2026. Additionally, Nyxoah detailed the conclusion of its collaboration with Cochlear Limited, ongoing patent litigation with Inspire Medical Systems, and positive commercial progress in both Europe and the U.S.